Actuate Therapeutics (ACTU) Competitors $7.83 -0.26 (-3.21%) Closing price 10/15/2025 04:00 PM EasternExtended Trading$8.04 +0.22 (+2.75%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACTU vs. KROS, ESPR, MNPR, CMPS, SIGA, MLTX, SVRA, AQST, ZVRA, and NAGEShould you be buying Actuate Therapeutics stock or one of its competitors? The main competitors of Actuate Therapeutics include Keros Therapeutics (KROS), Esperion Therapeutics (ESPR), Monopar Therapeutics (MNPR), COMPASS Pathways (CMPS), Siga Technologies (SIGA), MoonLake Immunotherapeutics (MLTX), Savara (SVRA), Aquestive Therapeutics (AQST), Zevra Therapeutics (ZVRA), and Niagen Bioscience (NAGE). These companies are all part of the "pharmaceutical products" industry. Actuate Therapeutics vs. Its Competitors Keros Therapeutics Esperion Therapeutics Monopar Therapeutics COMPASS Pathways Siga Technologies MoonLake Immunotherapeutics Savara Aquestive Therapeutics Zevra Therapeutics Niagen Bioscience Actuate Therapeutics (NASDAQ:ACTU) and Keros Therapeutics (NASDAQ:KROS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, media sentiment, risk, dividends, earnings and institutional ownership. Which has stronger earnings & valuation, ACTU or KROS? Actuate Therapeutics has higher earnings, but lower revenue than Keros Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioActuate TherapeuticsN/AN/A-$27.28MN/AN/AKeros Therapeutics$3.55M165.80-$187.35M$0.3146.74 Which has more volatility & risk, ACTU or KROS? Actuate Therapeutics has a beta of -0.23, indicating that its share price is 123% less volatile than the S&P 500. Comparatively, Keros Therapeutics has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500. Do analysts rate ACTU or KROS? Actuate Therapeutics presently has a consensus target price of $20.33, indicating a potential upside of 159.68%. Keros Therapeutics has a consensus target price of $30.00, indicating a potential upside of 107.04%. Given Actuate Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Actuate Therapeutics is more favorable than Keros Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Actuate Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50Keros Therapeutics 1 Sell rating(s) 7 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.40 Is ACTU or KROS more profitable? Keros Therapeutics has a net margin of 8.06% compared to Actuate Therapeutics' net margin of 0.00%. Keros Therapeutics' return on equity of 2.96% beat Actuate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Actuate TherapeuticsN/A N/A -281.83% Keros Therapeutics 8.06%2.96%2.74% Does the media prefer ACTU or KROS? In the previous week, Keros Therapeutics had 8 more articles in the media than Actuate Therapeutics. MarketBeat recorded 9 mentions for Keros Therapeutics and 1 mentions for Actuate Therapeutics. Actuate Therapeutics' average media sentiment score of 0.83 beat Keros Therapeutics' score of 0.32 indicating that Actuate Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Actuate Therapeutics Positive Keros Therapeutics Neutral Do institutionals & insiders hold more shares of ACTU or KROS? 71.6% of Keros Therapeutics shares are held by institutional investors. 69.3% of Actuate Therapeutics shares are held by insiders. Comparatively, 20.6% of Keros Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryKeros Therapeutics beats Actuate Therapeutics on 8 of the 13 factors compared between the two stocks. Get Actuate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACTU and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACTU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACTU vs. The Competition Export to ExcelMetricActuate TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$188.04M$3.36B$6.12B$10.45BDividend YieldN/A2.30%5.73%4.77%P/E RatioN/A22.7785.3327.36Price / SalesN/A486.46601.99136.95Price / CashN/A46.7037.4661.86Price / Book783.0010.5512.566.81Net Income-$27.28M-$52.58M$3.32B$276.80M7 Day Performance-3.21%0.09%0.59%0.42%1 Month Performance11.22%15.61%10.52%7.86%1 Year Performance-3.09%15.13%75.05%41.24% Actuate Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACTUActuate Therapeutics1.9441 of 5 stars$7.83-3.2%$20.33+159.7%-5.7%$188.04MN/A0.0010KROSKeros Therapeutics2.7739 of 5 stars$15.57-0.4%$30.00+92.7%-76.0%$632.78M$232.84M50.26100News CoverageInsider TradeESPREsperion Therapeutics3.6903 of 5 stars$3.11-0.3%$7.00+125.0%+18.3%$628.05M$332.31M-6.36200MNPRMonopar Therapeutics2.7073 of 5 stars$98.10-1.4%$97.33-0.8%+1,655.7%$605.25MN/A-29.4610Analyst ForecastCMPSCOMPASS Pathways3.2289 of 5 stars$6.25-0.7%$16.29+160.8%+15.0%$599.15MN/A-3.39120News CoverageAnalyst ForecastSIGASiga Technologies1.5365 of 5 stars$8.37+1.6%N/A+24.9%$599.09M$138.72M7.4040Options VolumeMLTXMoonLake Immunotherapeutics2.9167 of 5 stars$9.16+5.8%$36.00+292.8%-79.4%$591.69MN/A-3.312Trending NewsGap UpHigh Trading VolumeSVRASavara3.0526 of 5 stars$3.41-1.6%$7.50+120.3%-1.4%$588.51MN/A-6.8120Trending NewsAnalyst UpgradeAnalyst RevisionAQSTAquestive Therapeutics2.6092 of 5 stars$5.88-1.6%$10.29+75.1%+50.1%$585.88M$44.13M-8.39160ZVRAZevra Therapeutics2.6236 of 5 stars$10.16-4.6%$24.00+136.3%+40.6%$568.71M$23.61M-48.2520Analyst ForecastHigh Trading VolumeNAGENiagen Bioscience3.0728 of 5 stars$7.12-1.9%$13.42+88.5%N/A$567.84M$116.30M33.91120 Related Companies and Tools Related Companies KROS Competitors ESPR Competitors MNPR Competitors CMPS Competitors SIGA Competitors MLTX Competitors SVRA Competitors AQST Competitors ZVRA Competitors NAGE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACTU) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A Millionaire With SEVEN Clicks? $1,000 in just seven stocks in 2004 could have turned into a million-dolla...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actuate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Actuate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
